← All trials
NCT00202800
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2002
- Primary completion
- Sep 1, 2007
- Completion date
- Jan 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- The Spectrum Health GroupLead sponsor
- Hackley HospitalCollaborator
- Grand Rapids Clinical Oncology ProgramOverall official - principal investigator
- Van Andel Research InstituteCollaborator
- Battle Creek Health SystemCollaborator
- Mecosta County General HospitalCollaborator
- Munson Medical CenterCollaborator
- Eli LillyCollaborator
- University of MichiganCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.